Table 3.
Therapeutic efficacy of the 1st-line therapy.
| Therapeutic Efficacy | ALL | Period 1 | Period 2 | Period 3 | p-Value |
|---|---|---|---|---|---|
| (2009–2013) | (2014–2018) | (2019–2022) | |||
| CR/PR/SD/PD/NE, n | 9/60/73/136/58 | 1/10/12/51/12 | 4/16/23/61/28 | 4/34/38/24/18 | <0.0001 |
| ORR, n (%) | 69 (20.5) | 11 (14.9) | 20 (19.2) | 38 (38.0) | 0.001 |
| DCR, n (%) | 142 (51.0) | 23 (31.1) | 43 (41.3) | 76 (76.0) | <0.0001 |
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; ORR, objective response rate; DCR, disease control rate.